NCT07184931View on ClinicalTrials.gov

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

PHASE3RecruitingINTERVENTIONAL
Enrollment

980

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

May 14, 2029

Study Completion Date

May 14, 2029

Conditions
Crohn's Disease
Interventions
DRUG

Duvakitug

Pharmaceutical form:Injection solution Route of administration:SC injection

DRUG

Placebo

Pharmaceutical form:Injection solution Route of administration:SC injection

Trial Locations (3)

33065

RECRUITING

Precision Clinical Research-Site Number: 8400059, Coral Springs

33126

RECRUITING

Regis Clinical Research, LLC-Site Number: 8400041, Miami

33186

RECRUITING

Correa Research Center-Site Number: 8400010, Miami

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Teva Branded Pharmaceutical Products R&D LLC

INDUSTRY

lead

Sanofi

INDUSTRY

NCT07184931 - An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease | Biotech Hunter | Biotech Hunter